Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Additional preclinical studies have demonstrated that Adventrx Pharmaceuticals' antiviral drug, Thiovir, is active against a chimeric avian/human influenza virus anfd influenza A.
Subscribe to our email newsletter
Adventrx plans to further investigate Thiovir efficacy against multiple H5N1 strains of avian influenza in both in vitro and in vivo studies in collaboration.
“We are encouraged by the results from two independent labs confirming Thiovir activity against multiple influenza viruses,” said Evan Levine, president and CEO for Adventrx. “We will continue to investigate Thiovir as a therapy for influenza viruses, including bird flu, and we look forward to announcing additional results.”
Thiovir is intended to deliver the benefits of the antiviral drug foscarnet, including broad spectrum antiviral activity, with the added benefit of improved bioavailability. Adventrx currently plans to file an investigational new drug application with the FDA in the first half of 2006 for testing of Thiovir in patients with HIV/AIDS.